Mabion (WSE:MAB) - Share price, News & Analysis

MAB fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	3/6
Financial Health	3/6
Dividends	0/6

MAB Stock Overview

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland.

Rewards

Revenue is forecast to grow 15.34% per year

Became profitable this year

Risk Analysis

Highly volatile share price over the past 3 months

Mabion Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mabion
Historical stock prices
Current Share Price	zł27.60
52 Week High	zł110.00
52 Week Low	zł22.60
Beta	0.75
1 Month Change	-1.43%
3 Month Change	-5.80%
1 Year Change	-54.75%
3 Year Change	-63.25%
5 Year Change	-70.95%
Change since IPO	104.75%

Recent News & Updates

Dec 22

Is Mabion (WSE:MAB) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Sep 11

Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Mabion S.A. ( WSE:MAB...

Shareholder Returns

	MAB	PL Biotechs	PL Market
7D	1.7%	-1.7%	6.3%
1Y	-54.8%	-39.0%	-42.2%

Return vs Industry: MAB underperformed the Polish Biotechs industry which returned -39% over the past year.

Return vs Market: MAB underperformed the Polish Market which returned -42.2% over the past year.

Price Volatility

Is MAB's price volatile compared to industry and market?
MAB volatility
MAB Average Weekly Movement	14.2%
Biotechs Industry Average Movement	7.1%
Market Average Movement	6.8%
10% most volatile stocks in PL Market	13.4%
10% least volatile stocks in PL Market	4.5%

Stable Share Price: MAB is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: MAB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

Founded	Employees	CEO	Website
2007	213	Krzysztof Kaczmarczyk	https://www.mabion.eu

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of malignant, autoimmune, and metabolic diseases. Its products include MabionCD20, MabionHER2, MabionEGFR, and MabionVEGF that are oncology drugs; and MabionVEGF_Fab to treat several diseases resulting in vision impairment.

Mabion Fundamentals Summary

How do Mabion's earnings and revenue compare to its market cap?
MAB fundamental statistics
Market Cap	zł446.07m
Earnings (TTM)	zł1.90m
Revenue (TTM)	zł56.87m

234.4x

P/E Ratio

7.8x

P/S Ratio

Is MAB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MAB income statement (TTM)
Revenue	zł56.87m
Cost of Revenue	zł0
Gross Profit	zł56.87m
Other Expenses	zł54.97m
Earnings	zł1.90m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 27, 2022

Earnings per share (EPS)	0.12
Gross Margin	100.00%
Net Profit Margin	3.35%
Debt/Equity Ratio	120.9%

How did MAB perform over the long term?

See historical performance and comparison

Valuation

Is Mabion undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

234.41x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: MAB (PLN27.6) is trading above our estimate of fair value (PLN11.67)

Significantly Below Fair Value: MAB is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: MAB is poor value based on its Price-To-Earnings Ratio (234.4x) compared to the Polish Biotechs industry average (35x).

PE vs Market: MAB is poor value based on its Price-To-Earnings Ratio (234.4x) compared to the Polish market (10.2x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MAB's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: MAB is overvalued based on its Price-To-Book Ratio (27.5x) compared to the PL Biotechs industry average (3.8x).

Future Growth

How is Mabion forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

15.3%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MAB's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if MAB's earnings are forecast to grow faster than the Polish market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MAB's revenue (15.3% per year) is forecast to grow faster than the Polish market (5.5% per year).

High Growth Revenue: MAB's revenue (15.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MAB's Return on Equity is forecast to be high in 3 years time (26.9%)

Past Performance

How has Mabion performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

7.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MAB has high quality earnings.

Growing Profit Margin: MAB became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: MAB has become profitable over the past 5 years, growing earnings by 7.8% per year.

Accelerating Growth: MAB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MAB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: MAB's Return on Equity (11.7%) is considered low.

Financial Health

How is Mabion's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: MAB's short term assets (PLN112.7M) do not cover its short term liabilities (PLN118.5M).

Long Term Liabilities: MAB's short term assets (PLN112.7M) exceed its long term liabilities (PLN57.4M).

Debt to Equity History and Analysis

Debt Level: MAB has more cash than its total debt.

Reducing Debt: MAB's debt to equity ratio has reduced from 352% to 120.9% over the past 5 years.

Debt Coverage: MAB's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if MAB's interest payments on its debt are well covered by EBIT.

Balance Sheet

Dividend

What is Mabion current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

1.85%

Forecast Dividend Yield

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MAB's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MAB has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

zł104k

CEO Compensation

CEO

Krzysztof Kaczmarczyk

Tenure

zł104,000

Compensation

Mr. Krzysztof Kaczmarczyk serves as Non-Executive Independent Director of Huuuge, Inc. He had been a Supervisory Board Member at CI Games S.A. until 2022. He served as an Independent Chairman of the Superv...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/26 00:00
End of Day Share Price	2022/05/26 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31